Gilead Buys Myogen To Strengthen Pulmonology Franchise
The $2.5 bil. deal will add a late-stage candidate, ambrisentan, for the treatment of pulmonary arterial hypertension to Gilead's pipeline.
The $2.5 bil. deal will add a late-stage candidate, ambrisentan, for the treatment of pulmonary arterial hypertension to Gilead's pipeline.